Wave Life Sciences reported Q2 2026 financial results, highlighting progress in its RNA medicine pipeline. The company initiated Phase 2a dosing of WVE-007 for obesity, showing promise in fat loss and cardiometabolic benefits. It also advanced RNA editing programs WVE-006 for alpha-1 antitrypsin deficiency and WVE-008 for PNPLA3 liver disease, with FDA discussions planned for accelerated approval. Wave ended Q2 with $490.6 million in cash, supporting operations into Q3 2028 despite a net loss of $69.4 million for the quarter. Upcoming milestones include Phase 2 trials for obesity combinations and investor updates in fall 2026.
Xior Student Housing, a Belgian REIT, is trading at a compelling 10.5x forward earnings with a near 8% dividend yield. Its EPRA earnings rose 4% year-over-year to €1.14 per share, driven by strong rental growth and steady demand for student housing. ...
Grayscale's ZCSH ETF increased its Zcash holdings by 28.4% to 596,269 ZEC, representing about 3.52% of the total circulating supply, within weeks of its August 25, 2026 launch. This growth was driven entirely by in-kind transfers, primarily from Gray...
Strategy Inc., led by Michael Saylor, hinted at a potential new bitcoin purchase with a recent "orange" signal on its holdings chart, following a two-week pause in buying. The company currently holds 845,050 BTC valued at about $67.9 billion, with an...
ConocoPhillips is rated Buy as its strong production in the US Lower 48 and potential oil price gains outweigh elevated geopolitical risks from its international operations in Qatar, Libya, Iraq, and Syria. In Q2, the company showed strong execution ...
Ares Capital (ARCC) has proven resilience in the direct lending market over 22 years, successfully navigating major economic downturns like the 2008 financial crisis, the 2015–2016 energy slump, and the 2020 pandemic. Its disciplined underwriting and...
